In:
Journal of Cardiovascular Pharmacology, Ovid Technologies (Wolters Kluwer Health), Vol. 80, No. 6 ( 2022-12), p. 781-782
Kurzfassung:
Atrial fibrillation is the most common arrhythmia, ranging from 0.1% in patients 〈 55 years to 〉 9% in octogenarian patients. Polypharmacotherapy is crucial in atrial fibrillation management, and in many of the concomitant comorbidities, such as hypertension, heart failure, coronary artery disease, and diabetes. However, polypharmacy represents a major concern because of the associated risks of adverse events onset, with an increased risk of all-cause mortality and cardiovascular mortality. In this study, we commented data reported by Tsagkaris et al comparing them with previous reports.
Materialart:
Online-Ressource
ISSN:
0160-2446
DOI:
10.1097/FJC.0000000000001363
Sprache:
Englisch
Verlag:
Ovid Technologies (Wolters Kluwer Health)
Publikationsdatum:
2022
ZDB Id:
2049700-3
SSG:
15,3
